And this question assumes a tick gut has one infection. Nope.
1. Treatment Started Late.
A disseminated infection involving the joints, nervous system, or heart can be harder and slower to recover from than early, localized erythema migrans. Delayed diagnosis is also associated with persistent symptoms.
2. Lyme Disease Was Initially Missed.
Not every patient recognizes a tick bite or develops/notices the classic erythema migrans lesion, allowing infection to progress before treatment begins.
3. Ignore Bartonella–In 20% of the Population, It Causes Over 100 Issues.
4. Ignore Babesia Testing, So at Least 1.4% Die.
5. Ignore the Biofilm, Which Is a Complex Antibiotic Barrier.
6. Ignore the Hibernating Persister Form.
7. Treat Lyme, Bartonella, and Babesia as if They Reproduce Quickly, E.g., 35,000x a Month When the Reality Is 1-30x a Month.
Requiring more than days or a couple of weeks. At least according to hundreds of papers.
8. Testing Was Performed Too Early.
Antibody tests can be negative during the first days or weeks of infection because antibodies have not yet developed. This can delay diagnosis and therefore treatment.
9. Inadequate Antibiotic Selection for the Manifestation.
Therapy should match the clinical syndrome. Lyme meningitis, carditis, arthritis, and uncomplicated erythema migrans do not necessarily require the same treatment approach.
10. Inadequate Treatment Duration or Incomplete Treatment.
A patient who never received the “recommended regimen” [a one-size-fits-all, machine view of the body]. cannot be assumed to have received adequate therapy. Importantly, this does not mean that extending treatment indefinitely improves outcomes.
11. Poor Adherence.
Missed doses, premature discontinuation, vomiting medication, or otherwise failing to complete an effective regimen can reduce actual antibiotic exposure.
12. Impaired Drug Absorption.
Gastrointestinal disease, vomiting, interacting drugs/supplements, or administration errors can sometimes reduce exposure to an oral antimicrobial.
13. Reinfection.
Though when I inherit relapsed folks it is usually a poor initial treatment. Successful treatment does not provide reliable lifelong immunity. A patient can acquire B. burgdorferi again from another infected tick. Recurrent erythema migrans after appropriate treatment can therefore represent new infection rather than persistence of the original infection.
14. Persistent Lyme Arthritis After Microbial Treatment.
Some patients continue to have synovitis after appropriate antibiotics. Current evidence supports an important postinfectious inflammatory/immunologic mechanism in this subgroup rather than assuming every persistent swollen joint contains viable Borrelia. Though hundreds of studies show persistent viability.
15. Residual Tissue Injury.
Eradicating an organism does not instantly reverse damage already produced in nerves, joints or other tissues. Symptoms therefore can outlast the infection itself.
16. Post-Treatment Lyme Disease Syndrome (PTLDS).
A subset of appropriately treated patients develops prolonged fatigue, musculoskeletal pain, cognitive complaints or related symptoms. I believe this is due to residual types of infections with long-acting particles present for months.
17. Persistent Immune Activation/Inflammation.
Infection can initiate inflammatory processes that may continue after the initial infectious trigger has been controlled.
18. Autoimmune or Autoreactive Phenomena.
Particularly in post-antibiotic Lyme arthritis, adaptive immune mechanisms and dysregulated inflammatory responses have been investigated as explanations for continuing disease after antimicrobial treatment.
19. Persistent Microbial Antigens or Debris.
Borrelial proteins, nucleic acids, peptidoglycan, or other microbial products can theoretically continue stimulating immunity
20. Borrelia Antibiotic-Tolerant Persisters — Demonstrated In Vitro.
Laboratory cultures of B. burgdorferi contain small subpopulations capable of surviving antibiotic exposure without possessing conventional genetic antibiotic resistance.
21. Stationary-Phase Organisms Show Altered Antibiotic Susceptibility In Vitro.
Nongrowing/stationary-phase Borrelia can be substantially harder to eradicate in culture than actively dividing organisms.
22. Borrelial Aggregates/Microcolonies Do Not Die With Basic Treatment.
Unmoving biofilm protected microcolonies have demonstrated greater tolerance to conventional Lyme antibiotics.
23. Possible Persistence After Treatment in Animal Models.
Some mouse and nonhuman-primate studies have detected Borrelia DNA/RNA, antigen, xenodiagnostic positivity, or occasionally cultivable organisms following treatment. Results vary substantially among models and laboratories.
24. Lab Animal Persistence.
25. Tissue Sequestration Is Biologically Plausible but Incompletely Established Clinically.
Borrelia disseminates into multiple tissues, and tissue localization can alter microbial physiology and antibiotic exposure. DNA is destroyed very fast in dead Lyme bacteria.
26. Different Borrelia Species/Genospecies.
Lyme borreliosis is produced by the B. burgdorferi sensu lato complex. B. burgdorferi sensu stricto predominates in North America, whereas B. afzelii and B. garinii, among others, are important in Europe. Clinical manifestations therefore vary geographically.
27. Different Organ Manifestations Require Different Interpretation.
Persistent neurologic symptoms, arthritis, fatigue, and recurrent erythema migrans may raise concerns that a cure was not achieved.
28. Tick-Borne Coinfection.
Ixodes ticks can transmit pathogens besides Borrelia. Based on 60 studies, Bartonella is carried by about 20% of humans. Babesiosis or anaplasmosis, for example, may coexist with Lyme disease, and treatment directed only at Borrelia would not cure those infections. But the number of unique infections inside the “sewer” tick is huge.
29. Coinfection Can Be Mistaken for Antibiotic-Resistant Lyme Disease.
Persistent fever, cytopenias, hemolysis, or other atypical findings should prompt consideration of another tick-borne infection rather than automatically escalating Lyme antibiotics. One issue is determining if the one or two treatments killed all 3-4 Lyme forms. Coinfection is the rule. It is not a rare event in ticks.
30. A Different Illness May Have Been Present From the Beginning.
Fibromyalgia, autoimmune disease, neurologic disorders, endocrine disease, sleep disorders and other conditions can produce symptoms resembling Lyme disease.
31. Lyme Disease Can Be Overdiagnosed.
Referral studies demonstrate that substantial numbers of patients labeled as having chronic Lyme disease ultimately have another diagnosis or no convincing evidence of previous Lyme infection.
32. Positive Antibodies Do Not Prove Ongoing Infection.
Borrelia antibodies can remain detectable for years after successful treatment. Consequently, persistent seropositivity should not be interpreted as evidence that living Borrelia remain.
33. Serology Cannot Be Used as a “Test of Cure.”
Antibody titers do not necessarily disappear following eradication. Repeated positive antibody testing can therefore create the false impression of microbiological treatment failure.
34. There Is Currently No Validated Routine Biomarker Proving That PTLDS Equals Persistent Viable Borrelia.
This is one of the central unresolved problems in the field. Persistent symptoms are real, but their presence alone does not demonstrate continuing infection.
35. Conversely, Absence of a Simple Positive Culture Does Not Completely Settle Every Mechanistic Question.
Borrelia is difficult to culture from many human tissues, which is one reason persistence continues to be experimentally investigated. But difficulty demonstrating that organisms cannot be cultured cannot itself be considered evidence that they persist.
36. Pain Amplification/Central Sensitization May Perpetuate Symptoms.
Following significant infection and inflammation, pain-processing systems can remain abnormal even when the initiating process has resolved. However, mammals show active infection after typical treatment.
37. Sleep Disruption Can Perpetuate Fatigue, Pain and Cognitive Problems.
Once established, insomnia or fragmented sleep can magnify symptoms that patients naturally attribute to continuing infection.
38. Deconditioning Can Become a Secondary Disease Burden.
Months of pain, fatigue and inactivity can produce loss of aerobic capacity and muscle strength, orthostatic intolerance and exercise intolerance. Eliminating the original infection would not instantly reverse these changes.
39. Jarisch-Herxheimer Reactions Typically Resolve Within a Week With the Same Dose, Unless the Dose Is Very High for Your Body and Strains.
At the same dose typically.
40. Persistent Symptoms Can Reflect Persistent Infection, Postinfectious Inflammation, Tissue Injury, Another Infection, Another Disease, or Combinations of These Mechanisms.
One infection society has 700 references on persistent infection after typical dosing.
41. Species and Strains Vary Greatly.
It is unlikely that every patient with persistent symptoms has exactly the same mechanism.
Key Full Traditional References
Lantos PM, Rumbaugh J, Bockenstedt LK, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America, American Academy of Neurology, and American College of Rheumatology: 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease. Clinical Infectious Diseases. 2021;72(1):e1-e48. doi:10.1093/cid/ciaa1215.
Marques A. Persistent symptoms after treatment for Lyme disease. Infectious Disease Clinics of North America. 2022;36(3):621-638.
Verschoor YL, et al. Persistent Borrelia burgdorferi sensu lato infection after antibiotic treatment: a systematic review of animal studies. Clinical Microbiology Reviews. 2023;36. doi:10.1128/cmr.00074-22.
Sharma B, Brown AV, Matluck NE, Hu LT, Lewis K. Borrelia burgdorferi, the causative agent of Lyme disease, forms drug-tolerant persister cells. Antimicrobial Agents and Chemotherapy. 2015;59(8):4616-4624. doi:10.1128/AAC.00864-15.
Feng J, Li T, Yee R, et al. Stationary phase persister/biofilm microcolony of Borrelia burgdorferi causes more severe disease in a mouse model of Lyme arthritis: implications for understanding persistence, post-treatment Lyme disease syndrome (PTLDS), and treatment failure. Discovery Medicine. 2019;27(148):125-138.
Bockenstedt LK, Mao J, Hodzic E, Barthold SW, Fish D. Detection of attenuated, noninfectious spirochetes in Borrelia burgdorferi-infected mice after antibiotic treatment. Journal of Infectious Diseases. 2002;186(10):1430-1437.
Hodzic E, Feng S, Holden K, Freet KJ, Barthold SW. Persistence of Borrelia burgdorferi following antibiotic treatment in mice. Antimicrobial Agents and Chemotherapy. 2008;52(5):1728-1736. doi:10.1128/AAC.01050-07.
Klempner MS, Hu LT, Evans J, et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. New England Journal of Medicine. 2001;345(2):85-92.
Krupp LB, Hyman LG, Grimson R, et al. Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial. Neurology. 2003;60(12):1923-1930.
Fallon BA, Keilp JG, Corbera KM, et al. A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. Neurology. 2008;70(13):992-1003.
Berende A, ter Hofstede HJM, Vos FJ, et al. Randomized trial of longer-term therapy for symptoms attributed to Lyme disease. New England Journal of Medicine. 2016;374:1209-1220.
Bottom Line
Few are taught more than 45 seconds, so ignoring all tick infections and Lyme forms untouched by Doxy and Amoxy leads to trouble.